The deal “fits like a glove” for BioMarin’s business, according to an analyst who also thinks there could be a “valuable” ...

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...

With Sanofi’s latest announcement, major drugmakers have now pledged more than $200 billion in new investment in the U.S. since February as the industry tries to placate Trump and possibly give him ...

A gene editing drug custom-made for a critically ill baby showed that, for some ultra-rare diseases, it’s possible to design ...

A federal jury found Amgen liable for violating antitrust and tort laws. Elsewhere, Allogene and Kyverna trimmed staff and ...

Iowa, suggested Congress could once again move to overhaul PBMs’ controversial business practices after legislators pass ...

ADARx Pharmaceuticals will work with AbbVie to make RNA interference medicines for a variety of disease areas, including ...

The potential $2 billion acquisition is the largest tied to MASH in almost a decade, Leerink Partners analyst Thomas Smith wrote in a Wednesday note to clients. The last of similar size was Allergan’s ...

The proposal would see the HHS set price targets other countries pay for certain medicines, kicking off a round of ...

The president claimed his “most-favored nation” proposal would reduce some pharmaceutical prices by as much as 80%, but the ...